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Research into the cell biology of intracellular pathogens
has provided information on host-pathogen interactions
and on the importance of lipids at various stages in the
interactions. Lipids are “gatekeepers” in important che-
mical reactions involving cell signaling during pathogen
docking, invasion and traffic in and out of cells. Work-
ing with the Novartis Institute for Tropical Diseases,
our team is exploring how TB takes advantage of nor-
mal cellular processes by using its own lipids to subvert
the host’s lipid signaling - allowing it to enter the host
cell and survive there. Our focus is on developing host
and pathogen biomarkers that correlate with TB infec-
tion in laboratory animals and in humans. We are per-
forming mass spectrometry-based multi-marker
quantification of lipids in tissue and body fluids (blood,
urine, sputum), specifically host lipids (e.g. phospholi-
pids and ceramides) and pathogen-derived lipids (e.g.
mycolates, LAM, etc.). Our research is focused on
laboratory animals and TB patients in clinical trials, to
be used both for drug efficacy studies as well as case
detection and monitoring of treatment response. For
analysis of the host response, lipids are extracted from
infected tissues and cells, isolated and analyzed by mass
spectrometry to develop a lipid profile, which is used to
identify the metabolic pathways involved in the infection
and the enzyme/protein that facilitates the process. This
technique is very sensitive - a drop of blood is poten-
tially enough to perform the analysis. For pathogen bio-
marker discovery, mycobacterial lipids are isolated
directly from small volumes of infected body fluids such
as sputum and subsequently quantified via mass spec-
trometry. We expect this research will be (i) useful in
providing a better description of mycobacterial bios-
ynthetic activity, which will be helpful in developing
new diagnostics, drugs and vaccines, and (ii) for the
development of lipid biomarker for TB case detection.
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